Technology Licensing

Extended particulate-based release technology

can be incorporated into dosage forms that are traditionally associated with immediate release.

The unique proprietary technology used within dozens of Tris Pharma products provides many competitive advantages that are the foundation of Tris’ standalone licensing business. LiquiXR can be adapted in a wide variety of formulations, including suspensions, chewable tablets, film strips, and orally disintegrating tablets (ODTs). Click below to learn more about the unique features of LiquiXR technology.

The unique proprietary technology used within dozens of Tris Pharma products provides many competitive advantages that are the foundation of Tris’ standalone licensing business. LiquiXR can be adapted in a wide variety of formulations, including suspensions, chewable tablets, film strips, and orally disintegrating tablets (ODTs). Click below to learn more about the unique features of LiquiXR technology.

CUSTOM DOSING
  • CUSTOM DOSING
  • COMBINATION PRODUCTS
  • TASTE MASKING
  • EASILY TAKEN ON THE GO
  • PLEASANT FEEL IN MOUTH
  • ROBUST COATING
  • TARGET POPULATION
  • MANUFACTURING
  • PROPRIETARY TECHNOLOGY

Sustained-release profiles can be customized for up to 24 hours and allow for dose titration of individual patient regimens.

Can be used for two or more drugs.

Sustained-release coating provides taste masking of drug.

Chewable tablets, like other tablets, are easy to transport; can be packaged as unit dose and easily kept in patient’s wallet or purse – great for PRN (as-needed) medications.

Very fine particles provide a non-gritty, pleasant mouth feel and swallowing without chewing does not change release characteristics.

Our proprietary flexible-coating technology does not allow breakage of film coating under high compression forces during tableting. The aqueous-based non-solvent coating provides for excellent product integrity and regulatory acceptance.

Ideal for a wide variety of patient types and age ranges.

Easy to manufacture with cGMP-compliant manufacturing capability.

A potent barrier to competition; virtually every other extended-release, solid-dose “pill” specifically says, “do not chew or crush” because it can cause dose dumping.

LiquiXR technology

Within LiquiXR, millions of small particles (about 100 microns) deliver the drug over time. Drug particles are complexed, then coated with an extremely robust and flexible particle coating. The resulting particles are highly durable and can be incorporated into dosage forms typically associated with immediate release, converting them to extended release. The platform has been validated by the FDA and there are multiple approved LiquiXR products, including the first-ever approved 24-hour extended-release oral liquid and first-ever extended-release chewable tablet.

LiquiXR technology

Within LiquiXR, millions of small particles (about 100 microns) deliver the drug over time. Drug particles are complexed, then coated with an extremely robust and flexible particle coating. The resulting particles are highly durable and can be incorporated into dosage forms typically associated with immediate release, converting them to extended release. The platform has been validated by the FDA and there are multiple approved LiquiXR products, including the first-ever approved 24-hour extended-release oral liquid and first-ever extended-release chewable tablet.